Flexible Methodology for Developing Mammalian Cell Lines - - BioPharm International


Flexible Methodology for Developing Mammalian Cell Lines

BioPharm International

Table 1. Clonal Cell Line Production During Bioreactor Manufacturing.
GPEx cell line engineering technology is a flexible cell line development methodology capable of shortening the time to clinic for recombinant proteins that require production in mammalian cells. Large quantities of recombinant proteins/antibodies can be produced from pooled cell lines along the path to candidate cell line selection, which in turn shortens timelines and eliminates the need for separate, large-scale transient transfection experiments. GPEx cell lines producing antibodies express at levels of 0.7–1.4 g/L in fed-batch bioreactor manufacturing using generic conditions. These levels are on the upper end of production needed to produce clinical material and will improve with more detailed cell line process development.

Paul Weiss, Ph.D, M.B.A., is president of the Gala Biotech business unit of Cardinal Health PTS, Gregory Bleck, Ph.D., is director of molecular biology, and Jennifer Franklin is quality control supervisor. Cardinal Health PTS, 8137 Forsythia St., Middleton WI, 1.608.824.9920, fax 1.608.824.9930,


1. Bleck GT. An alternative method for rapid generation of stable, high-expressing mammalian cell lines. Bioprocessing Journal 2005:September/October.

2. Andrake MD, Skalka AM. Retroviral integrase, putting the pieces together. J. Biol. Chem. 1996:271;33;19633-19636.

3. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003:300;1749-1751.

4. Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. Retroviral DNA integration: ASLV, HIV and MLV show distinct target site preferences. PLOS Biology 2004:2;8;1127-1137.

5. De Palma M, Montini E., Santoni de Sio FR, Benedicenti F, Gentile A, Medico E, Naldini L. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005:105;6; 2307-2315.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here